The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up

doi:10.3390/jpm11030186

. 2021 Mar 6;11(3):186.

doi: 10.3390/jpm11030186.

The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up

Adam Kern^{1

2}, Tomasz Stompór³, Jolanta Kiewisz⁴, Bartłomiej E Kraziński⁴, Jacek Kiezun⁴, Marta Kiezun⁵, Jerzy Górny², Ewa Sienkiewicz², Leszek Gromadziński¹, Dariusz Onichimowski^{6

7}, Jacek Bil⁸

Affiliations

¹ Department of Cardiology and Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
² Department of Cardiology, Voivodal Specialist Hospital in Olsztyn, 10-561 Olsztyn, Poland.
³ Department of Nephrology, Hypertension and Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
⁴ Department of Human Histology and Embryology, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
⁵ Department of Animal Anatomy and Physiology, Faculty of Biology and Biotechnology, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
⁶ Department of Anaesthesiology and Intensive Care, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, 10-561 Olsztyn, Poland.
⁷ Clinical Department of Anaesthesiology and Intensive Care, Voivodal Specialist Hospital in Olsztyn, 10-561 Olsztyn, Poland.
⁸ Department of Invasive Cardiology, Centre of Postgraduate Medical Education, 02-507 Warsaw, Poland.

PMID: 33800939
PMCID: PMC8001826
DOI: 10.3390/jpm11030186

The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up

Adam Kern et al. J Pers Med. 2021.

. 2021 Mar 6;11(3):186.

doi: 10.3390/jpm11030186.

Authors

Affiliations

¹ Department of Cardiology and Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
² Department of Cardiology, Voivodal Specialist Hospital in Olsztyn, 10-561 Olsztyn, Poland.
³ Department of Nephrology, Hypertension and Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
⁴ Department of Human Histology and Embryology, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
⁵ Department of Animal Anatomy and Physiology, Faculty of Biology and Biotechnology, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
⁶ Department of Anaesthesiology and Intensive Care, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, 10-561 Olsztyn, Poland.
⁷ Clinical Department of Anaesthesiology and Intensive Care, Voivodal Specialist Hospital in Olsztyn, 10-561 Olsztyn, Poland.
⁸ Department of Invasive Cardiology, Centre of Postgraduate Medical Education, 02-507 Warsaw, Poland.

PMID: 33800939
PMCID: PMC8001826
DOI: 10.3390/jpm11030186

Abstract

Sclerostin might play a role in atherosclerosis development. This study aimed to analyze the impact of baseline sclerostin levels on 9-year outcomes in patients without significant renal function impairment and undergoing coronary angiography. The primary study endpoint was the rate of major cardiovascular events (MACE), defined as a combined rate of myocardial infarction (MI), stroke, or death at 9 years. We included 205 patients with a mean age of 62.9 ± 0.6 years and 70.2% male. Median serum sclerostin concentration was 133.22 pg/mL (IQR 64.0-276.17). At 9 years, in the whole population, the rate of MACE was 34.1% (n = 70), MI: 11.2% (n = 23), stroke: 2.4% (n = 5), and death: 20.5% (n = 42). In the high sclerostin (>median) group, we observed statistically significant higher rates of MACE and death: 25.2% vs. 43.1% (HR 1.75, 95% CI 1.1-2.10, p = 0.02) and 14.6% vs. 26.5% (HR 1.86, 95% CI 1.02-3.41, p = 0.049), respectively. Similar relationships were observed in patients with chronic coronary syndrome and SYNTAX 0-22 subgroups. Our results suggest that sclerostin assessment might be useful in risk stratification, and subjects with higher sclerostin levels might have a worse prognosis.

Keywords: Klotho; bone metabolism; cardiovascular events; coronary angiography; coronary artery disease; death; multivessel disease; myocardial infarction; osteocyte; sclerostin; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 2**
Whole population—Kaplan–Meier curves for MACE, myocardial infarction, and all-cause death, respectively.

**Figure 3**
Chronic coronary syndrome population—Kaplan–Meier curves for MACE, myocardial infarction, and all-cause death, respectively.

**Figure 4**
Acute coronary syndrome population—Kaplan–Meier curves for MACE, myocardial infarction, and all-cause death, respectively.

**Figure 5**
SYNTAX 0–22 population—Kaplan–Meier curves for MACE, myocardial infarction, and all-cause death, respectively.

See this image and copyright information in PMC

Cited by

Ten-Year Outcomes in Patients Undergoing Simultaneous Coronary and Renal Angiography-Does Renal Artery Stenosis Matter?
Kern A, Stompór T, Bojko K, Sienkiewicz E, Pawlak S, Pawlak D, Poskrobko G, Andrasz E, Gromadziński L, Jalali R, Onichimowski D, Piwko G, Zalewski A, Bil J. Kern A, et al. J Clin Med. 2024 Jun 7;13(12):3374. doi: 10.3390/jcm13123374. J Clin Med. 2024. PMID: 38929903 Free PMC article.
Individualized Management of Patients with Coronary Artery Disease.
Bil J. Bil J. J Pers Med. 2022 Jul 29;12(8):1243. doi: 10.3390/jpm12081243. J Pers Med. 2022. PMID: 36013192 Free PMC article.
Association of serum sclerostin and osteoprotegerin levels with the presence, severity and prognosis in patients with acute myocardial infarction.
Shui X, Dong R, Wu Z, Chen Z, Wen Z, Tang L, Xie X, Chen L. Shui X, et al. BMC Cardiovasc Disord. 2022 May 11;22(1):213. doi: 10.1186/s12872-022-02654-1. BMC Cardiovasc Disord. 2022. PMID: 35546224 Free PMC article.

References

1. Dallas S.L., Prideaux M., Bonewald L.F. The osteocyte: An endocrine cell and more. Endocr. Rev. 2013;34:658–690. doi: 10.1210/er.2012-1026. - DOI - PMC - PubMed
1. Tresguerres F., Torres J., López-Quiles J., Hernández G., Vega J., Tresguerres I. The osteocyte: A multifunctional cell within the bone. Ann. Anat.—Anat. Anz. 2020;227:151422. doi: 10.1016/j.aanat.2019.151422. - DOI - PubMed
1. Carlson N., Axelsen M., Mortensen O.H., Pedersen R.S., Heaf J.G. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis. Blood Purif. 2017;44:122–128. doi: 10.1159/000465513. - DOI - PubMed
1. Andrukhova O., Slavic S., Smorodchenko A., Zeitz U., Shalhoub V., Lanske B., E Pohl E., Erben R.G. FGF 23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 2014;6:744–759. doi: 10.1002/emmm.201303716. - DOI - PMC - PubMed
1. Delanaye P., Cavalier E., Bouquegneau A., Khwaja A. Sclerostin levels in CKD patients: An important, but not definitive, step on the way to clinical use. Kidney Int. 2015;88:1221–1223. doi: 10.1038/ki.2015.258. - DOI - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Dallas S.L., Prideaux M., Bonewald L.F. The osteocyte: An endocrine cell and more. Endocr. Rev. 2013;34:658–690. doi: 10.1210/er.2012-1026. - DOI - PMC - PubMed

[2] Dallas S.L., Prideaux M., Bonewald L.F. The osteocyte: An endocrine cell and more. Endocr. Rev. 2013;34:658–690. doi: 10.1210/er.2012-1026. - DOI - PMC - PubMed

[3] Tresguerres F., Torres J., López-Quiles J., Hernández G., Vega J., Tresguerres I. The osteocyte: A multifunctional cell within the bone. Ann. Anat.—Anat. Anz. 2020;227:151422. doi: 10.1016/j.aanat.2019.151422. - DOI - PubMed

[4] Tresguerres F., Torres J., López-Quiles J., Hernández G., Vega J., Tresguerres I. The osteocyte: A multifunctional cell within the bone. Ann. Anat.—Anat. Anz. 2020;227:151422. doi: 10.1016/j.aanat.2019.151422. - DOI - PubMed

[5] Carlson N., Axelsen M., Mortensen O.H., Pedersen R.S., Heaf J.G. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis. Blood Purif. 2017;44:122–128. doi: 10.1159/000465513. - DOI - PubMed

[6] Carlson N., Axelsen M., Mortensen O.H., Pedersen R.S., Heaf J.G. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis. Blood Purif. 2017;44:122–128. doi: 10.1159/000465513. - DOI - PubMed

[7] Andrukhova O., Slavic S., Smorodchenko A., Zeitz U., Shalhoub V., Lanske B., E Pohl E., Erben R.G. FGF 23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 2014;6:744–759. doi: 10.1002/emmm.201303716. - DOI - PMC - PubMed

[8] Andrukhova O., Slavic S., Smorodchenko A., Zeitz U., Shalhoub V., Lanske B., E Pohl E., Erben R.G. FGF 23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 2014;6:744–759. doi: 10.1002/emmm.201303716. - DOI - PMC - PubMed

[9] Delanaye P., Cavalier E., Bouquegneau A., Khwaja A. Sclerostin levels in CKD patients: An important, but not definitive, step on the way to clinical use. Kidney Int. 2015;88:1221–1223. doi: 10.1038/ki.2015.258. - DOI - PubMed

[10] Delanaye P., Cavalier E., Bouquegneau A., Khwaja A. Sclerostin levels in CKD patients: An important, but not definitive, step on the way to clinical use. Kidney Int. 2015;88:1221–1223. doi: 10.1038/ki.2015.258. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up

Affiliations

The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources